Government-Owned Inventions; Availability for Licensing, 15704-15705 [E7-6066]
Download as PDF
<![CDATA[
15704
Federal Register / Vol. 72, No. 62 / Monday, April 2, 2007 / Notices
Estimated
number of
respondents
Type of respondent
Frequency of
response
Estimated
number of
responses
Average hours
per response
Annual hour
burden
Respondent
cost**
Pilot RDD screener only ..........................
Pilot RDD screener and interview ...........
Additional RDD screeners for advance
materials test ........................................
Pilot mail survey .......................................
RDD screener only ..................................
RDD screener and interview ....................
Mail survey ...............................................
Telephone screener only for mail followup ....................................................
Telephone screener and interview for
mail followup .........................................
133
200
1
2
133
400
.0833
*.2500
11
100
$176
1,600
450
640
2,333
3,500
3,500
1
1
1
2
1
450
640
2,333
7,000
3,500
.0833
.3333
.0833
*.2500
.3333
37
213
194
1,750
1,167
592
3,408
3,104
28,000
18,672
457
1
457
.0833
38
608
457
2
914
*.2500
229
3,664
Total ..................................................
11,670
........................
15,827
........................
3,739
59,824
hsrobinson on PROD1PC76 with NOTICES
* (0.833 + 0.4167) / 2 = 0.2500.
** Hourly wage rate = $16.00.
Request For Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments To OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding estimated public
burden and associated response time,
should be directed to the: Office of
Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Office for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Bradford
W. Hesse, PhD, Project Officer, National
Cancer Institute, NIH, EPN 4068, 6130
Executive Boulevard MSC 7365,
Bethesda, Maryland 20892–7365, or call
non-toll-free number 301–594–9904, or
FAX your request to 301–480–2198, or
E-mail your request, including your
address, to hesseb@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
VerDate Aug<31>2005
18:39 Mar 30, 2007
Jkt 211001
received within 30-days of the date of
this publication.
Dated: March 23, 2007.
Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National
Institutes of Health.
[FR Doc. E7–6064 Filed 3–30–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
High-Level Expression and Purification
of Untagged and Histidine-Tagged
Human Immunodeficiency Virus type-1
(HIV–1) Reverse Transcriptase
Description of Technology: This
invention includes plasmids and
protocols to express and purify large
quantities of histidine-tagged and
untagged HIV–1 reverse transcriptase
(RT). Conditions have been optimized
for overexpression and purification of
p66 and p51 heterodimer RT in E. coli.
High-level of expression was reached as
RT represented approximately 30%–
40% of total cell proteins. The subject
invention enables the purification of
large quantities of heterodimer RT
necessary for structural and kinetic
studies and facilitates subunit-specific
amino acid alterations essential for
structure/function investigations.
Applications: Research Tool.
Development Status: In vitro data
available.
Inventors: Samuel H. Wilson,
Rajendra Prasad, Esther W. Hou
(NIEHS).
Related Publication: EW Hou, R
Prasad, WA Beard, SH Wilson. Highlevel expression and purification of
untagged and histidine-tagged HIV–1
reverse transcriptase. Protein Expr Purif.
2004 Mar;34(1):75–86.
Patent Status: HHS Reference No. E–
141–2007/0—Research Tool.
Licensing Status: Available for nonexclusive licensing as biological
material and research tool.
Licensing Contact: Sally Hu, PhD;
301/435–5606; HuS@mail.nih.gov.
Methods of Determining the Prognosis
of an Adenocarcinoma
Description of Technology: Available
for licensing and commercial
development is a novel method for
determining the prognosis of a subject
with adenocarcinoma in an organ, such
E:\FR\FM\02APN1.SGM
02APN1
Federal Register / Vol. 72, No. 62 / Monday, April 2, 2007 / Notices
as the lung, and to aid in the selection
of a specific therapeutic regimen. Lung
adenocarcinoma (AC) is the
predominant histological subtype of
lung cancer, which is the leading cause
of cancer deaths worldwide. The risk of
metastasis remains substantial in AC
patients, even when a curative resection
of early-stage AC is performed. The
prognosis includes the determination of
the likelihood of survival, the likelihood
of metastasis, or both. The method
includes quantization of the expression
of a plurality of Th1 and Th2 cytokines
of interest in the adenocarcinoma and in
non-cancerous tissue in the organ.
Altered expression of one or more of the
Th1 and Th2 cytokines in the
adenocarcinoma as compared to the
non-cancerous tissue determines the
prognosis for the subject. The method is
capable of distinguishing patients with
lymph node metastasis versus those
with short term survival. Furthermore,
methods are provided for evaluating the
effectiveness of anti-cancer agents.
Applications: Prognosis of
adenocarcinoma, aid in the selection of
specific therapeutic regimens and
evaluation of the effectiveness of anticancer agents.
Development Status: The technology
is in early stage of development.
Inventors: Curtis C. Harris, Masahiro
Seike, Xin Wei Wang (NCI).
Patent Status:
1. U.S. Provisional Application No.
60/830,936 filed 14 Jul 2006 (HHS
Reference No. E–263–2006/0–US–01).
2. U.S. Provisional Application No.
60/885,101 filed 17 Jan 2007 (HHS
Reference No. E–085–2007/0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, PhD, M.B.A.; 301/
435–4507; thalhamc@mail.nih.gov.
hsrobinson on PROD1PC76 with NOTICES
Codon Optimized Genes for Subunit
Vaccines
Description of Technology: Available
for licensing from the NIH are gene
constructs that express immunogenic
proteins based on viral genes that have
been optimized for expression in
mammalian cells. Using vaccine vectors
expressing respiratory syncytial virus
(RSV) proteins from the optimized
genes, this technology was shown to
result in a potent RSV-specific cellular
immune responses with favorable
phenotypic patterns. Such optimized
genes could be essential for
development of an effective RSV
subunit vaccine. Further, this
optimization could have possible
application to gene-based vectors for
other viral vaccines.
VerDate Aug<31>2005
18:39 Mar 30, 2007
Jkt 211001
Potential Applications of Technology:
Vaccines; Improved protein expression.
Inventors: Barney S. Graham and
Teresa R. Johnson (VRC/NIAID).
Patent Status: U.S. Provisional
Application No. 60/872,071 filed 30
Nov 2006 (HHS Reference No. E–326–
2006/0–US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Susan Ano, PhD;
301/435–5515; anos@mail.nih.gov.
Dual Expression Vector for DNA
Vaccines
Description of Technology: Available
for licensing from the NIH is an
expression vector for improved DNA
vaccines. Activation of co-stimulatory
molecules (e.g. signaling molecules,
cytokines, chemokines) and the timing
of the activation are important for
adaptive immune response. This
technology describes a new vector that
expresses an antigen and a costimulatory molecule, the latter after a
delay to allow accumulation of the
antigen. It is known that in some
circumstances an optimal immune
response is achieved by administration
of a co-stimulatory molecule after
antigen delivery. The subject technology
improves upon the existing concept by
providing a vector for accomplishing
this optimization in a single step.
Exemplary animal studies have shown
that the delayed expression of some costimulatory molecules in important
signaling pathways resulted in
enhancement of the cellular and/or
humoral immune responses using HIV
Env as a representative antigen.
Potential Applications: Improved
DNA vaccines.
Inventors: Gary J. Nabel and Wataru
Akahata (VRC/NIAID).
Patent Status: 1. U.S. Provisional
Application No. 60/737,896 filed 18
Nov 2005 (HHS Reference No. E–043–
2006/0–US–01).
2. PCT Application No. PCT/US2006/
044552 filed 20 Nov 2006 (HHS
Reference No. E–043–2006/2–PCT–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Susan Ano, PhD;
301/435–5515; anos@mail.nih.gov.
Methods and Systems for Efficient
Analysis and Microdissection of Intact
Biological Specimens
Description of Technology: Efficient
and accurate analysis of intact biological
specimens is needed to provide
information related to a broad range of
pathologies as well as normal
physiological states. The available
technology includes novel systems,
methods, and platforms for selective
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
15705
analysis of biological material such as
whole cells, tissues and tumors. This
platform may be used to identify and
independently characterize specific
components, such as cells, proteins,
nucleic acids or other molecules that
make-up the specimen.
The methods include placing the
sample of interest on a surface such as
a membrane, and activating the surface
at selected sites adjacent to the section
of interest. The activated sites become
permeable and the cells or cell
components adjacent to the permeable
sites can then be selectively extracted
and their content analyzed by standard
biochemical procedures. In addition, the
extract may be applied to microarray
devices, such as cDNA arrays, for
analysis of gene expression etc. The
technique presents a convenient
alternative to existing methods of tissue
microdissection. For further
convenience, the technique can be
directly combined with a variety of
analytical devices such as ELISAs,
microarray biochips, or other devices
which include multiple regions carrying
multiple capture molecules.
Applications: Analysis of biological
specimens such as whole cell tissues
and tumors; High throughput analysis of
individual components of intact
biological specimens.
Inventors: Michael R. Emmert-Buck
(NCI), Chad R. Englert-Haldeman (NCI),
Robert F. Bonner (NICHD), and Lance A.
Liotta (NCI).
Patent Status: 1. Patent Cooperation
Treaty Application No. PCT/US01/
08095 filed 14 Mar 2001, which
published as WO 02/10751 on 07 Feb
2002; claiming priority to 26 Jul 2000
(HHS Reference No. E–197–2000/0–
PCT–02).
2. National Phase Applications in:
a. U.S., Serial No. 10/333,374 filed 10
Jul 2003 (HHS Reference No. E–197–
2000/0–US–03).
b. Canada, Serial No. 2415864 filed 14
Mar 2001 (HHS Reference No. E–197–
2000/0–CA–04).
c. Europe, Serial No. 01918647.0 filed
14 Mar 2001 (HHS Reference No. E–
197–2000/0–EP–05).
Licensing Status: Availability for nonexclusive or exclusive licensing.
Licensing Contact: Susan Ano, PhD;
301/435–5515; anos@mail.nih.gov.
Dated: March 26, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–6066 Filed 3–30–07; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\02APN1.SGM
02APN1
]]>Agencies
[Federal Register Volume 72, Number 62 (Monday, April 2, 2007)]
[Notices]
[Pages 15704-15705]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-6066]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
High-Level Expression and Purification of Untagged and Histidine-Tagged
Human Immunodeficiency Virus type-1 (HIV-1) Reverse Transcriptase
Description of Technology: This invention includes plasmids and
protocols to express and purify large quantities of histidine-tagged
and untagged HIV-1 reverse transcriptase (RT). Conditions have been
optimized for overexpression and purification of p66 and p51
heterodimer RT in E. coli. High-level of expression was reached as RT
represented approximately 30%-40% of total cell proteins. The subject
invention enables the purification of large quantities of heterodimer
RT necessary for structural and kinetic studies and facilitates
subunit-specific amino acid alterations essential for structure/
function investigations.
Applications: Research Tool.
Development Status: In vitro data available.
Inventors: Samuel H. Wilson, Rajendra Prasad, Esther W. Hou
(NIEHS).
Related Publication: EW Hou, R Prasad, WA Beard, SH Wilson. High-
level expression and purification of untagged and histidine-tagged HIV-
1 reverse transcriptase. Protein Expr Purif. 2004 Mar;34(1):75-86.
Patent Status: HHS Reference No. E-141-2007/0--Research Tool.
Licensing Status: Available for non-exclusive licensing as
biological material and research tool.
Licensing Contact: Sally Hu, PhD; 301/435-5606; HuS@mail.nih.gov.
Methods of Determining the Prognosis of an Adenocarcinoma
Description of Technology: Available for licensing and commercial
development is a novel method for determining the prognosis of a
subject with adenocarcinoma in an organ, such
[[Page 15705]]
as the lung, and to aid in the selection of a specific therapeutic
regimen. Lung adenocarcinoma (AC) is the predominant histological
subtype of lung cancer, which is the leading cause of cancer deaths
worldwide. The risk of metastasis remains substantial in AC patients,
even when a curative resection of early-stage AC is performed. The
prognosis includes the determination of the likelihood of survival, the
likelihood of metastasis, or both. The method includes quantization of
the expression of a plurality of Th1 and Th2 cytokines of interest in
the adenocarcinoma and in non-cancerous tissue in the organ. Altered
expression of one or more of the Th1 and Th2 cytokines in the
adenocarcinoma as compared to the non-cancerous tissue determines the
prognosis for the subject. The method is capable of distinguishing
patients with lymph node metastasis versus those with short term
survival. Furthermore, methods are provided for evaluating the
effectiveness of anti-cancer agents.
Applications: Prognosis of adenocarcinoma, aid in the selection of
specific therapeutic regimens and evaluation of the effectiveness of
anti-cancer agents.
Development Status: The technology is in early stage of
development.
Inventors: Curtis C. Harris, Masahiro Seike, Xin Wei Wang (NCI).
Patent Status:
1. U.S. Provisional Application No. 60/830,936 filed 14 Jul 2006
(HHS Reference No. E-263-2006/0-US-01).
2. U.S. Provisional Application No. 60/885,101 filed 17 Jan 2007
(HHS Reference No. E-085-2007/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Cristina Thalhammer-Reyero, PhD, M.B.A.; 301/
435-4507; thalhamc@mail.nih.gov.
Codon Optimized Genes for Subunit Vaccines
Description of Technology: Available for licensing from the NIH are
gene constructs that express immunogenic proteins based on viral genes
that have been optimized for expression in mammalian cells. Using
vaccine vectors expressing respiratory syncytial virus (RSV) proteins
from the optimized genes, this technology was shown to result in a
potent RSV-specific cellular immune responses with favorable phenotypic
patterns. Such optimized genes could be essential for development of an
effective RSV subunit vaccine. Further, this optimization could have
possible application to gene-based vectors for other viral vaccines.
Potential Applications of Technology: Vaccines; Improved protein
expression.
Inventors: Barney S. Graham and Teresa R. Johnson (VRC/NIAID).
Patent Status: U.S. Provisional Application No. 60/872,071 filed 30
Nov 2006 (HHS Reference No. E-326-2006/0-US-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Susan Ano, PhD; 301/435-5515; anos@mail.nih.gov.
Dual Expression Vector for DNA Vaccines
Description of Technology: Available for licensing from the NIH is
an expression vector for improved DNA vaccines. Activation of co-
stimulatory molecules (e.g. signaling molecules, cytokines, chemokines)
and the timing of the activation are important for adaptive immune
response. This technology describes a new vector that expresses an
antigen and a co-stimulatory molecule, the latter after a delay to
allow accumulation of the antigen. It is known that in some
circumstances an optimal immune response is achieved by administration
of a co-stimulatory molecule after antigen delivery. The subject
technology improves upon the existing concept by providing a vector for
accomplishing this optimization in a single step. Exemplary animal
studies have shown that the delayed expression of some co-stimulatory
molecules in important signaling pathways resulted in enhancement of
the cellular and/or humoral immune responses using HIV Env as a
representative antigen.
Potential Applications: Improved DNA vaccines.
Inventors: Gary J. Nabel and Wataru Akahata (VRC/NIAID).
Patent Status: 1. U.S. Provisional Application No. 60/737,896 filed
18 Nov 2005 (HHS Reference No. E-043-2006/0-US-01).
2. PCT Application No. PCT/US2006/044552 filed 20 Nov 2006 (HHS
Reference No. E-043-2006/2-PCT-01).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Susan Ano, PhD; 301/435-5515; anos@mail.nih.gov.
Methods and Systems for Efficient Analysis and Microdissection of
Intact Biological Specimens
Description of Technology: Efficient and accurate analysis of
intact biological specimens is needed to provide information related to
a broad range of pathologies as well as normal physiological states.
The available technology includes novel systems, methods, and platforms
for selective analysis of biological material such as whole cells,
tissues and tumors. This platform may be used to identify and
independently characterize specific components, such as cells,
proteins, nucleic acids or other molecules that make-up the specimen.
The methods include placing the sample of interest on a surface
such as a membrane, and activating the surface at selected sites
adjacent to the section of interest. The activated sites become
permeable and the cells or cell components adjacent to the permeable
sites can then be selectively extracted and their content analyzed by
standard biochemical procedures. In addition, the extract may be
applied to microarray devices, such as cDNA arrays, for analysis of
gene expression etc. The technique presents a convenient alternative to
existing methods of tissue microdissection. For further convenience,
the technique can be directly combined with a variety of analytical
devices such as ELISAs, microarray biochips, or other devices which
include multiple regions carrying multiple capture molecules.
Applications: Analysis of biological specimens such as whole cell
tissues and tumors; High throughput analysis of individual components
of intact biological specimens.
Inventors: Michael R. Emmert-Buck (NCI), Chad R. Englert-Haldeman
(NCI), Robert F. Bonner (NICHD), and Lance A. Liotta (NCI).
Patent Status: 1. Patent Cooperation Treaty Application No. PCT/
US01/08095 filed 14 Mar 2001, which published as WO 02/10751 on 07 Feb
2002; claiming priority to 26 Jul 2000 (HHS Reference No. E-197-2000/0-
PCT-02).
2. National Phase Applications in:
a. U.S., Serial No. 10/333,374 filed 10 Jul 2003 (HHS Reference No.
E-197-2000/0-US-03).
b. Canada, Serial No. 2415864 filed 14 Mar 2001 (HHS Reference No.
E-197-2000/0-CA-04).
c. Europe, Serial No. 01918647.0 filed 14 Mar 2001 (HHS Reference
No. E-197-2000/0-EP-05).
Licensing Status: Availability for non-exclusive or exclusive
licensing.
Licensing Contact: Susan Ano, PhD; 301/435-5515; anos@mail.nih.gov.
Dated: March 26, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-6066 Filed 3-30-07; 8:45 am]
BILLING CODE 4140-01-P
